Johnson & Johnson (J&J) announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
06 Aug 2020
03 Aug 2020
Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.
29 Jul 2020
The US International Development Finance Corporation (DFC) has agreed to provide a $765m loan to Eastman Kodak Company to help create a new pharmaceutical business unit.
23 Jul 2020
The US government has placed an order worth $1.95bn to Pfizer and BioNTech to procure 100 million doses of their BNT162 vaccine candidate for Covid-19.
21 Jul 2020
Pfizer, BioNTech announce agreement with UK for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval.
17 Jul 2020
Swiss pharmaceutical firm Novartis has announced that its Sandoz division will provide a portfolio of 15 not-for-profit generic and over-the-counter (OTC) medicines to developing countries to treat the patients with Covid-19 symptoms.
10 Jul 2020
03 Jul 2020
Global investment firm KKR today announced that it has entered into a definitive agreement to purchase a controlling stake in J.B. Chemicals & Pharmaceuticals Ltd. (NSE: JBCHEPHARM) (“J.B. Chemicals” or “the Company” or “JBCPL”), one of the leading Indian pharmaceutical companies specializing in branded formulations.
29 Jun 2020
US private equity firm Carlyle Group has agreed to acquire a stake of 20% stake in Piramal Pharma, the pharmaceutical business of Indian conglomerate Piramal Enterprises, in a deal worth up to $490m.
26 Jun 2020
Moderna and Catalent announce collaboration for fill-finish manufacturing of Moderna’s Covid-19 vaccine candidate
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Indiana.